Form 4: Avidity Biosciences Director Simona Skerjanec Receives Equity Compensation

Avidity Biosciences, Inc. Director Simona Skerjanec was granted 6,692 restricted stock units and options to purchase 10,034 shares of common stock as part of her compensation.

Summary

• Simona Skerjanec, a Director of Avidity Biosciences, Inc. (RNA), acquired 6,692 shares of common stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, with a reported acquisition price of $0.
• These RSUs are set to vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, contingent upon Ms. Skerjanec's continuous service.
• Additionally, Ms. Skerjanec was granted stock options to acquire 10,034 shares of common stock on June 10, 2025, with an exercise price of $33.62 per share.
• These stock options will also vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to her continuous service.
• The stock options have an expiration date of June 9, 2035.

Sentiment

Score: 7

Explanation: The sentiment is positive as the transaction represents routine equity compensation for a director, which aligns their interests with shareholders. It does not indicate any negative operational or financial news.

Positives

• The grant of restricted stock units and stock options to a director aligns their financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology industry.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Industry Context

Equity compensation, including restricted stock units and stock options, is a common and widely accepted practice in the biotechnology and pharmaceutical industries to compensate directors and executives, aligning their incentives with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to more focused efforts on long-term value creation.

Next Steps

• The Restricted Stock Units and stock options are expected to vest on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Simona Skerjanec